Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of P2203 in Healthy Volunteers
NCT06698861Phase 1Completed
- Sponsor
- PharmaEssentia
- Start
- Aug 2024
- Primary completion
- Feb 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pegfilgrastim in chemotherapy-induced neutropenia (CIN) (3 cohorts), sponsored by PharmaEssentia. Primary endpoints: Safety and tolerability of P2203 injection and Maximum tolerated dose of P2203. Started Aug 2024; status: completed.
02
Drugs
pegfilgrastim
03
Conditions
chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on NCT06698861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06698861.